{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:35:24Z","timestamp":1793831724593,"version":"4.6.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T00:00:00Z","timestamp":1628208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T00:00:00Z","timestamp":1628208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s12032-021-01558-y","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T15:03:24Z","timestamp":1628262204000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Possible protective effect of pantoprazole against cisplatin-induced nephrotoxicity in head and neck cancer patients: a randomized controlled trial"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8823-145X","authenticated-orcid":false,"given":"Eman","family":"Ghonaim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"El-Haggar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzy","family":"Gohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,6]]},"reference":[{"key":"1558_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40620-017-0392-z","volume":"31","author":"S Manohar","year":"2018","unstructured":"Manohar S, Leung N. Cisplatin nephrotoxicity: a review of the literature. J Nephrol. 2018;31:15\u201325. https:\/\/doi.org\/10.1007\/s40620-017-0392-z.","journal-title":"J Nephrol"},{"key":"1558_CR2","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.3390\/toxins2112490","volume":"2","author":"RP Miller","year":"2010","unstructured":"Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins (Basel). 2010;2:2490\u2013518. https:\/\/doi.org\/10.3390\/toxins2112490.","journal-title":"Toxins (Basel)"},{"key":"1558_CR3","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/967826","author":"A Ozkok","year":"2014","unstructured":"Ozkok A, Edelstein CL. Pathophysiology of cisplatin-induced acute kidney injury. Biomed Res Int. 2014. https:\/\/doi.org\/10.1155\/2014\/967826.","journal-title":"Biomed Res Int"},{"key":"1558_CR4","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/sj.ki.5002786","volume":"73","author":"N Pabla","year":"2008","unstructured":"Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008;73:994\u20131007. https:\/\/doi.org\/10.1038\/sj.ki.5002786.","journal-title":"Kidney Int"},{"key":"1558_CR5","doi-asserted-by":"publisher","first-page":"332","DOI":"10.5935\/0101-2800.20130052","volume":"35","author":"LAB Peres","year":"2013","unstructured":"Peres LAB, da Cunha AD. Acute nephrotoxicity of cisplatin: molecular mechanisms. J Bras Nefrol \u02b9org\u00e3o Of Soc Bras e Latino-Americana Nefrol. 2013;35:332\u201340. https:\/\/doi.org\/10.5935\/0101-2800.20130052.","journal-title":"J Bras Nefrol \u02b9org\u00e3o Of Soc Bras e Latino-Americana Nefrol"},{"key":"1558_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1758835920923430","volume":"12","author":"ZY Duan","year":"2020","unstructured":"Duan ZY, Cai GY, Li JJ, Chen XM. Cisplatin-induced renal toxicity in elderly people. Ther Adv Med Oncol. 2020;12:1\u201315. https:\/\/doi.org\/10.1177\/1758835920923430.","journal-title":"Ther Adv Med Oncol"},{"key":"1558_CR7","doi-asserted-by":"publisher","first-page":"5238","DOI":"10.3390\/ijms20205238","volume":"20","author":"DM Tanase","year":"2019","unstructured":"Tanase DM, Gosav EM, Radu S, Costea CF, Ciocoiu M, Carauleanu A, et al. The predictive role of the biomarker kidney molecule-1 (KIM-1) in acute kidney injury (AKI) cisplatin-induced nephrotoxicity. Int J Mol Sci. 2019;20:5238. https:\/\/doi.org\/10.3390\/ijms20205238.","journal-title":"Int J Mol Sci"},{"key":"1558_CR8","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.2353\/ajpath.2010.090610","volume":"176","author":"G Ciarimboli","year":"2010","unstructured":"Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B, et al. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol. 2010;176:1169\u201380. https:\/\/doi.org\/10.2353\/ajpath.2010.090610.","journal-title":"Am J Pathol"},{"key":"1558_CR9","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1016\/S0002-9440(10)61234-5","volume":"167","author":"G Ciarimboli","year":"2005","unstructured":"Ciarimboli G, Ludwig T, Lang D, Pavenst\u00e4dt H, Koepsell H, Piechota HJ, et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005;167:1477\u201384. https:\/\/doi.org\/10.1016\/S0002-9440(10)61234-5.","journal-title":"Am J Pathol"},{"key":"1558_CR10","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1158\/1078-0432.CCR-14-0319","volume":"20","author":"JA Sprowl","year":"2014","unstructured":"Sprowl JA, Lancaster CS, Pabla N, Hermann E, Kosloske AM, Gibson AA, et al. Cisplatin-induced renal injury is independently mediated by OCT2 and p53. Clin Cancer Res. 2014;20:4026\u201335. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0319.","journal-title":"Clin Cancer Res"},{"key":"1558_CR11","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/clpt.2009.139","volume":"86","author":"KK Filipski","year":"2009","unstructured":"Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther. 2009;86:396\u2013402. https:\/\/doi.org\/10.1038\/clpt.2009.139.","journal-title":"Clin Pharmacol Ther"},{"key":"1558_CR12","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.medine.2013.09.003","volume":"38","author":"M Seijas","year":"2014","unstructured":"Seijas M, Baccino C, Nin N, Lorente JA. Definition and biomarkers of acute renal damage: new perspectives. Med Intensiva. 2014;38:376\u201385. https:\/\/doi.org\/10.1016\/j.medine.2013.09.003.","journal-title":"Med Intensiva"},{"issue":"7","key":"1558_CR13","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1177\/1078155220901756","volume":"26","author":"E Ghadrdan","year":"2020","unstructured":"Ghadrdan E, Ebrahimpour S, Sadighi S, Chaibakhsh S, Jahangard-Rafsanjani Z. Evaluation of urinary neutrophil gelatinase-associated lipocalin and urinary kidney injury molecule-1 as biomarkers of renal function in cancer patients treated with cisplatin. J Oncol Pharm Pract. 2020;26(7):1643\u20139. https:\/\/doi.org\/10.1177\/1078155220901756.","journal-title":"J Oncol Pharm Pract"},{"key":"1558_CR14","doi-asserted-by":"publisher","unstructured":"Kubrak T, Podg\u00f3rski R, Aebisher D, Gala-B\u0142\u0105dzi\u0144ska A. The significance of NGAL and KIM-1 proteins for diagnosis of acute kidney injury (AKI) in clinical practice. Eur J Clin Exp Med 2018;16:28-33. https:\/\/doi.org\/10.15584\/ejcem.2018.1.4.","DOI":"10.15584\/ejcem.2018.1.4"},{"key":"1558_CR15","doi-asserted-by":"publisher","unstructured":"Ajay M, G R, Gottipati SS, Babu P S. A concise review on extensive use of proton pump inhibitors. Transl Med 2018;08:8\u201310. https:\/\/doi.org\/10.4172\/2161-1025.1000204.","DOI":"10.4172\/2161-1025.1000204"},{"key":"1558_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5009\/gnl15502","volume":"11","author":"DS Strand","year":"2017","unstructured":"Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: a comprehensive review. Gut Liver. 2017;11:27\u201337. https:\/\/doi.org\/10.5009\/gnl15502.","journal-title":"Gut Liver"},{"issue":"7","key":"1558_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022163","volume":"6","author":"AT Nies","year":"2011","unstructured":"Nies AT, Hofmann U, Resch C, Schaeffeler E, Rius M, Schwab M. Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs). PLoS ONE. 2011;6(7): e22163. https:\/\/doi.org\/10.1371\/journal.pone.0022163.","journal-title":"PLoS ONE"},{"key":"1558_CR18","unstructured":"Cancer Therapy Evaluation Program (CTEP). Common Terminology Criteria for Adverse Events (CTCAE).v.5.0 [5x7]. Cancer Ther Eval Progr 2017:155. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Accessed 5 Feb 2021."},{"key":"1558_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31\u201341. https:\/\/doi.org\/10.1159\/000180580.","journal-title":"Nephron"},{"key":"1558_CR20","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3109\/10408444.2011.602662","volume":"41","author":"PD Snchez-Gonzlez","year":"2011","unstructured":"Snchez-Gonzlez PD, L\u00f3pez-Hern\u00e1ndez FJ, L\u00f3pez-Novoa JM, Morales AI. An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity. Crit Rev Toxicol. 2011;41:803\u201321. https:\/\/doi.org\/10.3109\/10408444.2011.602662.","journal-title":"Crit Rev Toxicol"},{"key":"1558_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-019-0518-9","volume":"26","author":"V Volarevic","year":"2019","unstructured":"Volarevic V, Djokovic B, Jankovic MG, Harrell CR, Fellabaum C, Djonov V, et al. Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity. J Biomed Sci. 2019;26:1\u201314. https:\/\/doi.org\/10.1186\/s12929-019-0518-9.","journal-title":"J Biomed Sci"},{"key":"1558_CR22","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1093\/ckj\/sfx007","volume":"10","author":"V Bunel","year":"2017","unstructured":"Bunel V, Tournay Y, Baudoux T, De Prez E, Marchand M, Mekinda Z, et al. Early detection of acute cisplatin nephrotoxicity: interest of urinary monitoring of proximal tubular biomarkers. Clin Kidney J. 2017;10:639\u201347. https:\/\/doi.org\/10.1093\/ckj\/sfx007.","journal-title":"Clin Kidney J"},{"key":"1558_CR23","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1002\/ptr.5345","volume":"29","author":"F Shahbazi","year":"2015","unstructured":"Shahbazi F, Sadighi S, Dashti-Khavidaki S, Shahi F, Mirzania M, Abdollahi A, et al. Effect of silymarin administration on cisplatin nephrotoxicity: report from a pilot, randomized, double-blinded, Placebo-controlled clinical. Trial Phyther Res. 2015;29:1046\u201353. https:\/\/doi.org\/10.1002\/ptr.5345.","journal-title":"Trial Phyther Res"},{"key":"1558_CR24","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s00280-008-0711-0","volume":"61","author":"V Launay-Vacher","year":"2008","unstructured":"Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M. Prevention of cisplatin nephrotoxicity: State of the art and recommendations from the european society of clinical pharmacy special interest group on cancer care. Cancer Chemother Pharmacol. 2008;61:903\u20139. https:\/\/doi.org\/10.1007\/s00280-008-0711-0.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1558_CR25","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.toxlet.2015.06.012","volume":"237","author":"T Karasawa","year":"2015","unstructured":"Karasawa T, Steyger PS. An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol Lett. 2015;237:219\u201327. https:\/\/doi.org\/10.1016\/j.toxlet.2015.06.012.","journal-title":"Toxicol Lett"},{"key":"1558_CR26","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/gm298","volume":"3","author":"E Schaeffeler","year":"2011","unstructured":"Schaeffeler E, Hellerbrand C, Nies AT, Winter S, Kruck S, Hofmann U, van der Kuip H, Zanger UM, Koepsell HSM. DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. Genome Med. 2011;3:82. https:\/\/doi.org\/10.1186\/gm298.","journal-title":"Genome Med"},{"key":"1558_CR27","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/tpj.2011.60","volume":"13","author":"L Chen","year":"2013","unstructured":"Chen L, Hong C, Chen EC, Yee SW, Xu L, Almof EU, et al. Genetic and epigenetic regulation of the organic cation transporter 3, SLC22A3. Pharmacogenomics J. 2013;13:110\u201320. https:\/\/doi.org\/10.1038\/tpj.2011.60.","journal-title":"Pharmacogenomics J"},{"key":"1558_CR28","doi-asserted-by":"publisher","first-page":"547","DOI":"10.6064\/2012\/473829","volume":"550","author":"G Ciarimboli","year":"2014","unstructured":"Ciarimboli G. Membrane transporters as mediators of cisplatin side-effects. Anticancer Res. 2014;550:547\u201350. https:\/\/doi.org\/10.6064\/2012\/473829.","journal-title":"Anticancer Res"},{"key":"1558_CR29","doi-asserted-by":"publisher","DOI":"10.5812\/numonthly.87523","volume":"11","author":"SS Shariatmaghani","year":"2019","unstructured":"Shariatmaghani SS, Saadat A, Nazar I, Davoudi F, Parvin S, Mehrani H, et al. Urinary neutrophil gelatinase associated lipocalin (NGAL) in predicting Cisplatin-Induced acute kidney injury. Nephrourol Mon. 2019;11: e87523. https:\/\/doi.org\/10.5812\/numonthly.87523.","journal-title":"Nephrourol Mon"},{"key":"1558_CR30","doi-asserted-by":"publisher","first-page":"296","DOI":"10.4236\/pp.2013.43043","volume":"04","author":"S Tezcan","year":"2013","unstructured":"Tezcan S, Izzettin FV, Sancar M, Yumuk PF, Turhal S. Nephrotoxicity evaluation in outpatients treated with cisplatin-based chemotherapy using a short hydration method. Pharmacol & Pharm. 2013;04:296\u2013302. https:\/\/doi.org\/10.4236\/pp.2013.43043.","journal-title":"Pharmacol & Pharm"},{"key":"1558_CR31","doi-asserted-by":"publisher","first-page":"280","DOI":"10.5935\/0101-2800.20140041","volume":"36","author":"LAB Peres","year":"2014","unstructured":"Peres LAB, da Cunha AD, Assump\u00e7\u00e3o RAB, Sch\u00e4fer A, da Silva AL, Gaspar AD, et al. Evaluation of the cisplatin nephrotoxicity using the urinary neutrophil gelatinase-associated lipocalin (NGAL) in patients with head and neck cancer. J Bras Nefrol. 2014;36:280\u20138. https:\/\/doi.org\/10.5935\/0101-2800.20140041.","journal-title":"J Bras Nefrol"},{"key":"1558_CR32","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/cpt.606","volume":"101","author":"B George","year":"2017","unstructured":"George B, Wen X, Mercke N, Gomez M, O\u2019Bryant C, Bowles DW, et al. Profiling of kidney injury biomarkers in patients receiving cisplatin: time-dependent changes in the absence of clinical nephrotoxicity. Clin Pharmacol Ther. 2017;101:510\u20138. https:\/\/doi.org\/10.1002\/cpt.606.","journal-title":"Clin Pharmacol Ther"},{"key":"1558_CR33","doi-asserted-by":"publisher","unstructured":"Maeda A, Ando H, Ura T, Muro K, Aoki M, Saito K, et al. Differences in urinary renal failure biomarkers in cancer patients initially treated with cisplatin. Anticancer Res 2017;37:5235\u20135239. https:\/\/doi.org\/10.21873\/anticanres.11947.","DOI":"10.21873\/anticanres.11947"},{"key":"1558_CR34","first-page":"305","volume":"9","author":"F Shahbazi","year":"2015","unstructured":"Shahbazi F, Sadighi S, Dashti-Khavidaki S, Shahi F, Mirzania M. Urine ratio of neutrophil gelatinase-associated lipocalin to creatinine as a marker for early detection of cisplatinassociated nephrotoxicity. Iran J Kidney Dis. 2015;9:305\u201310.","journal-title":"Iran J Kidney Dis"},{"key":"1558_CR35","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.kjms.2012.10.004","volume":"29","author":"HYH Lin","year":"2013","unstructured":"Lin HYH, Lee SC, Lin SF, Hsiao HH, Liu YC, Yang WC, et al. Urinary neutrophil gelatinase-associated lipocalin levels predict cisplatin-induced acute kidney injury better than albuminuria or urinary cystatin C levels. Kaohsiung J Med Sci. 2013;29:304\u201311. https:\/\/doi.org\/10.1016\/j.kjms.2012.10.004.","journal-title":"Kaohsiung J Med Sci"},{"key":"1558_CR36","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s00280-015-2880-y","volume":"76","author":"H Shinke","year":"2015","unstructured":"Shinke H, Masuda S, Togashi Y, Ikemi Y, Ozawa A, Sato T, et al. Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients. Cancer Chemother Pharmacol. 2015;76:989\u201396. https:\/\/doi.org\/10.1007\/s00280-015-2880-y.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1558_CR37","doi-asserted-by":"publisher","first-page":"806","DOI":"10.3109\/0886022X.2016.1163154","volume":"38","author":"LD Karademir","year":"2016","unstructured":"Karademir LD, Dogruel F, Kocyigit I, Yazici C, Unal A, Sipahioglu MH, et al. The efficacy of theophylline in preventing cisplatin-related nephrotoxicity in patients with cancer. Ren Fail. 2016;38:806\u201314. https:\/\/doi.org\/10.3109\/0886022X.2016.1163154.","journal-title":"Ren Fail"},{"key":"1558_CR38","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/ki.2010.317","volume":"79","author":"A Linkermann","year":"2011","unstructured":"Linkermann A, Himmerkus N, R\u00f6lver L, Keyser KA, Steen P, Br\u00e4sen JH, et al. Renal tubular Fas ligand mediates fratricide in cisplatin-induced acute kidney failure. Kidney Int. 2011;79:169\u201378. https:\/\/doi.org\/10.1038\/ki.2010.317.","journal-title":"Kidney Int"},{"key":"1558_CR39","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1080\/0886022X.2018.1456938","volume":"40","author":"H Soni","year":"2018","unstructured":"Soni H, Kaminski D, Gangaraju R, Adebiyi A. Cisplatin-induced oxidative stress stimulates renal fas ligand shedding. Ren Fail. 2018;40:314\u201322. https:\/\/doi.org\/10.1080\/0886022X.2018.1456938.","journal-title":"Ren Fail"},{"key":"1558_CR40","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00280-017-3296-7","volume":"79","author":"K Ikemura","year":"2017","unstructured":"Ikemura K, Oshima K, Enokiya T, Okamoto A, Oda H, Mizuno T, et al. Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study. Cancer Chemother Pharmacol. 2017;79:943\u20139. https:\/\/doi.org\/10.1007\/s00280-017-3296-7.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1558_CR41","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s00210-020-01823-3","volume":"393","author":"RS Ismail","year":"2020","unstructured":"Ismail RS, El-Awady MS, Hassan MH. Pantoprazole abrogated cisplatin-induced nephrotoxicity in mice via suppression of inflammation, apoptosis, and oxidative stress. Naunyn Schmiedebergs Arch Pharmacol. 2020;393:1161\u201371. https:\/\/doi.org\/10.1007\/s00210-020-01823-3.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"1558_CR42","doi-asserted-by":"publisher","unstructured":"Hiramatsu S ichi, Ikemura K, Fujisawa Y, Iwamoto T, Okuda M. Concomitant lansoprazole ameliorates cisplatin-induced nephrotoxicity by inhibiting renal organic cation transporter 2 in rats. Biopharm Drug Dispos 2020;41:239\u2013247. https:\/\/doi.org\/10.1002\/bdd.2242.","DOI":"10.1002\/bdd.2242"},{"key":"1558_CR43","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1634\/theoncologist.2018-0037","volume":"23","author":"E Fox","year":"2018","unstructured":"Fox E, Levin K, Zhu Y, Segers B, Balamuth N, Womer R, et al. Pantoprazole, an inhibitor of the organic cation transporter 2, does not ameliorate cisplatin-related ototoxicity or nephrotoxicity in children and adolescents with newly diagnosed osteosarcoma treated with methotrexate, doxorubicin, and cisplatin. Oncologist. 2018;23:762. https:\/\/doi.org\/10.1634\/theoncologist.2018-0037.","journal-title":"Oncologist"},{"key":"1558_CR44","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/hdi.12196","volume":"18","author":"PL Carron","year":"2014","unstructured":"Carron PL, Padilla M, Maurizi BJ. Nephrotic syndrome and acute renal failure during pegylated liposomal doxorubicin treatment. Hemodial Int. 2014;18:846\u20137. https:\/\/doi.org\/10.1111\/hdi.12196.","journal-title":"Hemodial Int"},{"key":"1558_CR45","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1053\/j.ajkd.2012.08.048","volume":"61","author":"N Mohamed","year":"2013","unstructured":"Mohamed N, Goldstein J, Schiff J, John R. Collapsing glomerulopathy following anthracycline therapy. Am J Kidney Dis. 2013;61:778\u201381. https:\/\/doi.org\/10.1053\/j.ajkd.2012.08.048.","journal-title":"Am J Kidney Dis"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01558-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-021-01558-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01558-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T06:51:39Z","timestamp":1629787899000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-021-01558-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,6]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1558"],"URL":"https:\/\/doi.org\/10.1007\/s12032-021-01558-y","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,6]]},"assertion":[{"value":"23 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the Research Ethics Committee of Tanta University and was carried out in compliance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants provided an informed consent before being enrolled in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable as no personal data is included.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"108"}}